Zacks Research Research Analysts Boost Earnings Estimates for ResMed Inc. (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Research analysts at Zacks Research boosted their Q2 2025 earnings estimates for shares of ResMed in a report released on Tuesday, September 10th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.19 per share for the quarter, up from their prior estimate of $2.16. The consensus estimate for ResMed’s current full-year earnings is $8.91 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.23 EPS, Q4 2025 earnings at $2.29 EPS, FY2025 earnings at $8.72 EPS, Q2 2026 earnings at $2.26 EPS, Q4 2026 earnings at $2.45 EPS, FY2026 earnings at $9.29 EPS and FY2027 earnings at $10.15 EPS.

Other research analysts have also issued research reports about the company. Needham & Company LLC lowered ResMed from a “buy” rating to a “hold” rating and set a $236.00 price objective for the company. in a research report on Wednesday, September 4th. Royal Bank of Canada raised their price target on ResMed from $204.00 to $206.00 and gave the company a “sector perform” rating in a report on Friday, August 2nd. KeyCorp lifted their price target on ResMed from $238.00 to $251.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Citigroup downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Monday, June 24th. Finally, StockNews.com cut shares of ResMed from a “buy” rating to a “hold” rating in a report on Friday, August 30th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $204.70.

ResMed Stock Down 0.9 %

NYSE:RMD opened at $250.71 on Wednesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.59 and a quick ratio of 1.69. The firm’s 50-day moving average price is $220.87 and its 200-day moving average price is $206.37. The company has a market capitalization of $36.83 billion, a PE ratio of 38.51, a P/E/G ratio of 2.44 and a beta of 0.69. ResMed has a 1-year low of $132.24 and a 1-year high of $255.18.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.05. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.22 billion. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.60 earnings per share.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 19th. Investors of record on Thursday, August 15th will be issued a $0.53 dividend. The ex-dividend date is Thursday, August 15th. This represents a $2.12 annualized dividend and a yield of 0.85%. This is a boost from ResMed’s previous quarterly dividend of $0.48. ResMed’s dividend payout ratio (DPR) is currently 32.57%.

Insider Buying and Selling at ResMed

In other news, CFO Brett Sandercock sold 1,000 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $194.35, for a total value of $194,350.00. Following the transaction, the chief financial officer now directly owns 90,056 shares in the company, valued at approximately $17,502,383.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO Brett Sandercock sold 1,000 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $194.35, for a total value of $194,350.00. Following the transaction, the chief financial officer now owns 90,056 shares in the company, valued at approximately $17,502,383.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Justin Leong sold 48,000 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total transaction of $10,419,360.00. Following the completion of the transaction, the insider now owns 18,741 shares in the company, valued at approximately $4,068,108.87. The disclosure for this sale can be found here. In the last ninety days, insiders sold 97,931 shares of company stock worth $21,382,007. Insiders own 1.21% of the company’s stock.

Institutional Investors Weigh In On ResMed

A number of hedge funds have recently modified their holdings of RMD. Dorsey & Whitney Trust CO LLC grew its holdings in ResMed by 3.7% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 1,473 shares of the medical equipment provider’s stock valued at $292,000 after purchasing an additional 52 shares during the period. QRG Capital Management Inc. grew its stake in shares of ResMed by 4.5% during the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 56 shares during the period. Inspire Advisors LLC increased its holdings in ResMed by 1.9% in the 2nd quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider’s stock worth $586,000 after acquiring an additional 56 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in ResMed by 1.9% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 3,188 shares of the medical equipment provider’s stock worth $631,000 after acquiring an additional 60 shares in the last quarter. Finally, Gulf International Bank UK Ltd raised its stake in ResMed by 0.5% during the 1st quarter. Gulf International Bank UK Ltd now owns 12,614 shares of the medical equipment provider’s stock worth $2,497,000 after acquiring an additional 66 shares during the period. Institutional investors own 54.98% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.